CDSCO

The Central Drugs Standard Control Organization (CDSCO) has released its July 2026 Not of Standard Quality (NSQ) drug alert, listing a large number of medicine samples that failed to meet specified quality standards during testing by state and CDSCO laboratories.

The Subject Expert Committee (Oncology) of the Central Drugs Standard Control Organisation (CDSCO) has recommended granting permission to conduct a Phase IV clinical trial of dostarlimab in adult patients in India with primary advanced or recurrent endometrial cancer. The recommendation was made during the SEC (Oncology) meeting held on August 5, 2026, at CDSCO Headquarters, New Delhi.

The Central Drugs Standard Control Organisation (CDSCO) has clarified that applications seeking permission to import and market new drugs that are not approved anywhere in the world, where Phase III Global Clinical Trials (GCTs) are either ongoing or have been completed with the participation of Indian subjects, will be examined and processed by the Investigational New Drug (IND) Division.